Uneek Mehra - 01 Apr 2026 Form 4 Insider Report for BridgeBio Oncology Therapeutics, Inc. (BBOT)

Reporting relationship: Former Officer
Issuer ticker: BBOT
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 May 2026, 19:01:37 UTC
Prior SEC filing: 12 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Aaron Chan, Attorney-in-Fact

Key filing fact

Uneek Mehra filed Form 4 for BridgeBio Oncology Therapeutics, Inc. (BBOT) on 05 May 2026.

Key facts

This page summarizes Uneek Mehra's Form 4 filing for BridgeBio Oncology Therapeutics, Inc. (BBOT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 May 2026, 19:01.

Change

Previous filing in this sequence was filed on 12 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001881504 Primary reporting owner

Mehra Uneek

Relationship: Former Officer
Address: BRIDGEBIO ONCOLOGY THERAPEUTICS, INC., 256 EAST GRAND AVENUE, SUITE 104, SOUTH SAN FRANCISCO
Signature: /s/ Aaron Chan, Attorney-in-Fact
Signature date: 05 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BBOT transaction

Common Stock

Tax liability

Transaction value
Shares: -524
Change %: -2.2%
Price: $9.03^*
Shares after: 22,806
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Uneek Mehra is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.